Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Inclusion Criteria

• •Subject must have a diagnosis of Rheumatoid Arthritis (RA) at Screening, as defined by the 2010 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria (Aletaha D et al, 2010)
• •Subject must have a positive Rheumatoid Factor (RF) and/or a positive anti-Cyclic Citrullinated Peptide antibody (anti-CCP) as determined by the central laboratory at Screening
• •Subject must have moderate to severe RA disease at Screening and Baseline defined as:
• •1. Screening (all criteria required)
• •* ≥ 4 swollen joints (of 28 prespecified joints)
• •* Disease Activity Score \[Erythrocyte Sedimentation Rate\] (DAS28\[ESR\]) \> 3.2
• •* C-Reactive Protein (CRP) concentration ≥ 10 mg/L (or 1.0 mg/dL) or Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hr
• •2. Baseline (both criteria required)
• •* ≥ 4 swollen joints (of 28 prespecified joints)
• •* Disease Activity Score \[Erythrocyte Sedimentation Rate\] (DAS28\[ESR\]) \> 3.2
• •Subject must have inadequately responded previously to Methotrexate (MTX)
• •Subject is using MTX 15 to 25 mg/week orally or subcutaneously at Screening and has used the same MTX regimen for a minimum of 28 days prior to Baseline